BURLINGTON, ON, Sept. 20 /CNW/ - THE JENEX CORPORATION (TSX Venture
Exchange: JEN and Frankfurt: JNX), announced it has been featured in Larry
Oakley's Stock Pick editorial at www.WallStreetCorner.com.
Oakley said as part of his editorial: "I interviewed President Michael A.
Jenkins and feel this company is a winner. After receiving samples of its main
products, my enthusiasm has substantially increased. I really like the
appreciation potential of this situation. The market is huge for both
products. I like the fact that it is now entering its commercialization phase,
a good time in my opinion to take a modest position, prior to the time the
investing public understands the potential that exists here."
He added: "You may be acquainted with Abreva. It's advertised as the only
non-prescription COLD SORE medicine approved by the FDA to shorten healing
time & duration of symptoms. I have been told that GlaxoSmithKline (NYSE: GSK)
... licensed Abreva for North America, in a five year deal that included $25
million in up-front fees and royalties to Avanir Pharmaceuticals. Abreva's
claim is to shorten duration. Jenex's Non-invasive Medical Device called
interceptCS(TM) actually prevents the cold sore from erupting!"
About The Jenex Corporation: Jenex has a Non-invasive Medical Device that
prevents the eruption of "cold sores." The interceptCS(TM) Cold Sore
Prevention System is approved in Canada and received CE approval for European
Union countries. Jenex also has a product called Therapik(R). It could be
described as "Sting No More." It immediately relieves the pain & itch caused
by stings & bites. It has FDA approval. Both products use Jenex's Thermal
Therapy (heat technology) that is patented in the U.S., Canada, Australia, &
Europe. The company's Mission statement: "Inform and educate the public about
our safe and effective products that have been clinically proven and approved
to provide improved life style benefits." Vision statement: "Commercialization
of our patented product line allowing Jenex to be the pre-eminent leader in
cold sore prevention and insect bite & sting relief." Jenex has the potential
to dominate two huge underdeveloped markets. Check www.interceptCS.com and
www.jenexcorp.com for details.
About WallStreetCorner.com: Formed eight years ago by Larry Oakley, known
as the "Elder Statesman of Emerging Growth Company Writers," as a venue for
his Conservative Speculator newsletter published since 1987,
www.WallStreetCorner.com, including the corporate profiles of its
participants, Conservative Speculator, and Oakley's "Stock Pick," "Opinion,"
"Comment," "Bold Ventures," and "Economic Comments" editorial columns, is now
regularly read by investors in 93 countries.
The TSX Venture Exchange Inc. has not reviewed and does not accept
responsibility for the accuracy or the contents of this press release. Certain
information included in this press release is forward-looking and is subject
to important risks and uncertainties. The results or events predicted in these
statements may differ materially from actual results or events.
For further information:
For further information: Michael A. Jenkins, President, Phone: (905)
632-3830, Email: firstname.lastname@example.org, Website: www.JenexCorp.com